WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555973
CAS#: 2308497-58-5
Description: ZUN97585, also known as FGFR1/DDR2 inhibitor 1, is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity. This compound was first reported in Eur J Med Chem. 2019 Feb 1;163:671-689. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to Hodoodo Chemical Nomenclature (see web page: https://www.hodoodo.com/page/naming).
Hodoodo Cat#: H555973
Name: ZUN97585
CAS#: 2308497-58-5
Chemical Formula: C28H22F3N5O
Exact Mass: 501.18
Molecular Weight: 501.513
Elemental Analysis: C, 67.06; H, 4.42; F, 11.36; N, 13.96; O, 3.19
Synonym: ZUN97585; ZUN-97585; ZUN 97585;
IUPAC/Chemical Name: 3-(3-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
InChi Key: ZEOWTGPWHLSLOG-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H22F3N5O/c1-16-5-6-18(27(37)33-21-4-2-3-20(13-21)28(29,30)31)11-24(16)17-7-10-23-25(12-17)34-35-26(23)19-14-32-36(15-19)22-8-9-22/h2-7,10-15,22H,8-9H2,1H3,(H,33,37)(H,34,35)
SMILES Code: O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC=C(C)C(C3=CC4=C(C=C3)C(C5=CN(C6CC6)N=C5)=NN4)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 501.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
[1]. Wang Q, et al. Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma. Eur J Med Chem. 2019 Feb 1;163:671-689.
